.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
McKinsey
Healthtrust
QuintilesIMS
Covington
Harvard Business School
Colorcon
Baxter
UBS
Moodys

Generated: November 19, 2017

DrugPatentWatch Database Preview

ESBRIET Drug Profile

« Back to Dashboard

What is the patent landscape for Esbriet, and what generic Esbriet alternatives are available?

Esbriet is a drug marketed by Genentech Inc and is included in two NDAs. There are twenty patents protecting this drug.

This drug has two hundred and forty patent family members in forty-one countries.

The generic ingredient in ESBRIET is pirfenidone. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pirfenidone profile page.

Pharmacology for ESBRIET

Ingredient-typePyridones
Drug ClassPyridone
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► SubscribeY ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-001Jan 11, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
CAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-003Jan 11, 2017RXYesYes► Subscribe► Subscribe ► Subscribe
Genentech Inc
ESBRIET
pirfenidone
TABLET;ORAL208780-002Jan 11, 2017DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ESBRIET

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,867,516Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient► Subscribe
9,017,722Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ESBRIET

Country Document Number Estimated Expiration
Canada2710358► Subscribe
Ukraine99433► Subscribe
Peru06832011► Subscribe
South Korea20070093006► Subscribe
Germany60234812► Subscribe
Georgia, Republic ofP20166426► Subscribe
CroatiaP20110959► Subscribe
China102811719► Subscribe
Denmark2191831► Subscribe
Hong Kong1206937► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Queensland Health
UBS
Cantor Fitzgerald
US Department of Justice
Harvard Business School
Fuji
Fish and Richardson
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot